title: A targeted IL-15 fusion protein with potent anti-tumor activity.
abstract: IL-15 has been actively investigated for its potential in tumor immunotherapy. To enhance the anti-tumor activity of IL-15, the novel PFC-1 construct was designed, which comprises the following 3 parts: (1) IL-15Rα fused with IL-15 to enhance IL-15 activity, (2) an Fc fragment to increase protein half-life, and (3) an integrin-targeting RGD peptide to enhance tumor targeting. PFC-1 showed tumor cell targeting without compromising IL-15 activity. PFC-1 also had potent anti-tumor activities in xenograft models, suggesting the potential application of this multi-functional fusion protein in tumor therapy.
authors.affiliation: a School of Pharmaceutical Sciences; Sun Yat-Sen University ; Guangzhou , PR China.|b Centre for Cellular & Structural Biology; Sun Yat-Sen University ; Guangzhou , PR China.
authors.forename: Siqi
authors.initials: S
authors.lastname: Chen
authors.affiliation: a School of Pharmaceutical Sciences; Sun Yat-Sen University ; Guangzhou , PR China.|b Centre for Cellular & Structural Biology; Sun Yat-Sen University ; Guangzhou , PR China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Huang
authors.affiliation: a School of Pharmaceutical Sciences; Sun Yat-Sen University ; Guangzhou , PR China.|b Centre for Cellular & Structural Biology; Sun Yat-Sen University ; Guangzhou , PR China.
authors.forename: Jiayu
authors.initials: J
authors.lastname: Liu
authors.affiliation: a School of Pharmaceutical Sciences; Sun Yat-Sen University ; Guangzhou , PR China.|b Centre for Cellular & Structural Biology; Sun Yat-Sen University ; Guangzhou , PR China.
authors.forename: Jieyu
authors.initials: J
authors.lastname: Xing
authors.affiliation: c Peking University Cancer Hospital; Beijing Institute for Cancer Research ; Beijing , PR China.
authors.forename: Ning
authors.initials: N
authors.lastname: Zhang
authors.affiliation: d Health Division of Guard Bureau; General Staff Department of PLA ; Beijing , PR China.
authors.forename: Yawei
authors.initials: Y
authors.lastname: Liu
authors.affiliation: a School of Pharmaceutical Sciences; Sun Yat-Sen University ; Guangzhou , PR China.|b Centre for Cellular & Structural Biology; Sun Yat-Sen University ; Guangzhou , PR China.
authors.forename: Zhong
authors.initials: Z
authors.lastname: Wang
authors.affiliation: a School of Pharmaceutical Sciences; Sun Yat-Sen University ; Guangzhou , PR China.|b Centre for Cellular & Structural Biology; Sun Yat-Sen University ; Guangzhou , PR China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Li
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D061307:Human Umbilical Vein Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000502:physiology; D008175:Lung Neoplasms / Q000517:prevention & control* / Q000556:secondary; D008546:Melanoma, Experimental / Q000188:drug therapy* / Q000556:secondary; D008810:Mice, Inbred C57BL; D058990:Molecular Targeted Therapy; D009368:Neoplasm Transplantation; D011993:Recombinant Fusion Proteins / Q000494:pharmacology*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D039302:Integrin alphaVbeta3; C000608763:PFC-1 peptide; D011993:Recombinant Fusion Proteins
keywords: IL-15; IL-15Rα; RGD; fusion protein; tumor immunotherapy